Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.63 |
| ▸ | PNMT | P11086 | 2/20 | 0.58 |
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | DBH | P09172 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30252677 | 1.00 | TAAR1 (0.63) | TAAR1PNMTIDO1KDM4EALDH1A1 | |
| SCHEMBL81786 | 0.87 | TAAR1 (0.59) | TAAR1PNMTIDO1KDM4EALDH1A1 | |
| SCHEMBL320795 | 0.81 | TAAR1 (0.60) | TAAR1PNMTIDO1TSHR | |
| SCHEMBL490393 | 0.81 | PNMT (0.62) | TAAR1PNMTIDO1KDM4EALDH1A1 | |
| SCHEMBL29447950 | 0.81 | TAAR1 (0.60) | TAAR1PNMTIDO1TSHR | |
| SCHEMBL25392754 | 0.80 | TAAR1 (0.41) | TAAR1PNMTIDO1ALDH1A1CYP1A2 | |
| SCHEMBL15863955 | 0.79 | PNMT (0.60) | TAAR1PNMTIDO1KDM4EALDH1A1 | |
| Benzene SCHEMBL28092155 | 0.79 | TAAR1 (0.58) | TAAR1PNMTIDO1TSHR | |
| SCHEMBL8440317 | 0.79 | TAAR1 (0.39) | TAAR1PNMTCYP3A4 | |
| SCHEMBL30252554 | 0.78 | TAAR1 (0.44) | TAAR1PNMTIDO1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115427410-B | Amide or sulfonamide derivatives and application thereof | 苏州恩华生物医药科技有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-115427410-A | Amide or sulfonamide derivative and application thereof | 苏州恩华生物医药科技有限公司 | 2022-12-02 | — | — | CN | disclosed |
| US-11192907-B2 | Aminopeptidase A inhibitors and pharmaceutical compositions comprising the same | QUANTUM GENOMICS (FR) | 2021-12-07 | — | — | US | disclosed |
| WO-2021213353-A1 | AMIDE OR SULFONAMIDE DERIVATIVE AND USE THEREOF | 苏州恩华生物医药科技有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| US-20210309678-A1 | AMINOPEPTIDASE A INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Institut National de la Santé et de la Recherche Médicale (FR) | 2021-10-07 | — | — | US | disclosed |
| CN-113166182-A | Aminopeptidase A inhibitor and pharmaceutical composition comprising the same | 量子基因公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-102666545-B | As the heterocycle Pyrazolopyrimidine analogs of JAK inhibitor | CELLZOME LTD. (GB) | 2016-04-06 | — | — | CN | disclosed |
| CN-104395310-A | Bicyclic substituted uracils and their use | Bayer Pharma AG | 2015-03-04 | — | — | CN | disclosed |
| CN-104039791-A | [1,2,3] triazolo [4,5-D ] pyrimidine derivatives as cannabinoid receptor 2 agonists | HOFFMANN LA ROCHE | 2014-09-10 | — | — | CN | disclosed |
| CN-103930426-A | [1, 2, 3] triazolo [4, 5 -d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 | HOFFMANN LA ROCHE | 2014-07-16 | — | — | CN | disclosed |
| US-8476285-B2 | Purine-core inhibitors of HSP90 and their use in treating cancer | MYREXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20100016586-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2010-01-21 | — | — | US | disclosed |
| US-7595401-B2 | Therapeutic compounds and their use in cancer | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| EP-2038041-A2 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | Myriad Genetics, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2007134298-A2 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-4292453-A | REACTION OF A HALO DERIVATIVE OF BETA-BROMOETHYLBENZENE WITH AQUEOUS ALKALI AND A QUATERNARY PHASE TRANSFER CATALYST | MAKHTESHIM CHEMICAL WORKS LTD. (IL) | 1981-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192907-B2 | Aminopeptidase A inhibitors and pharmaceutical compositions comprising the same | ANPEP, DNPEP, ENPEP | TAAR1 4206/4885PNMT 2466/4885IDO1 303/4885 |
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MCL1, TP53, TUBB3 | TAAR1 4673/4885PNMT 2057/4885IDO1 4505/4885 |
| US-20100016586-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MCL1, TP53, TUBB3 | TAAR1 4673/4885PNMT 2057/4885IDO1 4505/4885 |
| US-20210309678-A1 | AMINOPEPTIDASE A INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | ANPEP, DNPEP, ENPEP | TAAR1 4206/4885PNMT 2466/4885IDO1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.